November 2016 Patients who received transcranial magnetic stimulation (TMS) were more likely to abstain from cocaine than patients who received medications for symptoms associated with abstinence. Researchers concluded that TMS appears to be safe and its efficacy as a treatment for cocaine addiction deserves to be evaluated in a larger clinical trial.
October 2016 Public health messages can increase public approval for making naloxone legally available to friends and relatives of opioid users to administer if an overdose occurs.
September 2016 Patients who don’t take their medications as prescribed often put themselves at risk for problems including misdiagnoses, complications, and death. A study suggests that adding low doses of quinine to patients’ medications could provide an inexpensive, reliable, and safe method of monitoring whether patients are taking their medications as directed.
August 2016 Treatment with an extended-release stimulant medication plus cognitive behavioral therapy was associated with reductions in cocaine use and in attention-deficit/hyperactivity disorder symptoms in patients with both disorders.
July 2016
During investigations into using transcranial brain stimulation (TMS) to treat cocaine abuse, two projects take diverging paths. One researcher moves to the next stage, while another is forced to cut his trial short.
May 2016 Treatment that combines use of Bp/Nx and memantine may enable young adults addicted to opioids establish lasting abstinence after a relatively brief course of medication-assisted therapy, a pilot trial suggests.
April 2016 When lobeline turned out not to be the answer, it became a starting point. Dr. Linda Dwoskin and her team set out to transform the molecule into something more effective and with fewer side effects.
March 2016 This NIDA Notes animation depicts a basic experiment that researchers use to test whether a prospective new medication can prevent relapse to drug addiction.
January 2016 Emergency department visits present prime opportunities to identify people with opioid addiction and provide them with onsite initiation of treatment with buprenorphine/naloxone.
November 2015 In the first long-term follow-up of patients treated with buprenorphine/naloxone for addiction to opioid pain relievers, half reported that they were abstinent from the drugs 18 months after starting the therapy.
